GlobeNewswire·Nov 12, 2026, 8:13 PM ET

Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights

FDA feedback on the proposed use of a new brilaroxazine formulation for the RECOVER-2 trial & future NDA is expected in Q4 2026.
The U.S. Patent Office granted priority examination (Track 1) for a composition of matter patent covering the new brilaroxazine formulation, with protection potentially extending through 2046.
Patient enrollment in the RECOVER-2 Phase 3 trial is targeted for the first half of 2027, subject to securing additional financing.
A bioequivalence study to confirm the comparability of the new brilaroxazine formulation is planned to initiate in Q1 2027.
Reviva reported a net loss of approximately $2.3 million ($0.17 per share) for Q3 2026, compared to a $4.0 million loss in the prior year period.
Cash & cash equivalents totaled approximately $17.5 million as of September 30, 2026, up from $14.4 million at the end of 2025.
The company anticipates filing an application to relist its common stock (RVPH) on the Nasdaq exchange in the first half of 2027.
Additional publications regarding brilaroxazine for schizophrenia treatment are expected over the next six months.
Reviva is actively pursuing partnership opportunities to advance its pipeline of CNS, inflammatory, & cardiometabolic therapies.